Price History

Hover for the daily close. The dotted line marks the period open.

Compare QNRX with… →

QNRX Key Statistics

As of Sep 4, 2026

Trading

Open: $7.64
Previous Close: $7.87
Day's Range: 7.10–7.69
52-Week Range: 3.25–41.80
Volume: 78.70K
Beta: 1.73

Valuation

Market Cap: $14.58M
P/E Ratio: unprofitable
EPS (ttm): −5.67

Financials (FY)

Revenue (FY): $0.00
Net Income (FY): −$15.80M
Profit margin: 0.00%
Shares Outstanding: 2.01M
1-Year Return: −4.79%

Dividend and dates

Avg Volume: 764.76K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

QNRX Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

+126.54%−93.76%−49.69%

2016*2017201820192020202120222023202420252026*

Year	Return
2026 (partial year)	−49.69%
2025	−36.67%
2024	−86.73%
2023	−71.21%
2022	−93.76%
2021	−78.94%
2020	−2.70%
2019	−78.86%
2018	−70.00%
2017	+126.54%
2016 (partial year)	−37.70%

As of September 4, 2026.

QNRX Revenue and Earnings by Fiscal Year

FY ends December

RevenueNet income

2022202320242025

Fiscal year	Revenue	Net income	Net margin
2025	$0.00	−$15.80M	—
2024	$0.00	−$8.96M	—
2023	$0.00	−$8.69M	—
2022	$0.00	−$9.38M	—

Fiscal year	Revenue	Gross profit	Operating income	Net income	Net margin
2025	$0.00	—	−$16.29M	−$15.80M	—
2024	$0.00	—	−$9.53M	−$8.96M	—
2023	$0.00	—	−$9.38M	−$8.69M	—
2022	$0.00	—	−$9.26M	−$9.38M	—

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

QNRX Valuation vs Biotechnology Median

Median of 656 stocks

Metric	QNRX	Biotechnology median	vs median
Profit margin	0.00%	0.00%	0.0 pts above

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Quoin Pharmaceuticals, Ltd. (QNRX) carries a market capitalisation of $14.58M. It is classified in the Biotechnology industry, within the Healthcare sector. Headcount on file is 4.

The 52-week range on file runs from $3.25 to $41.80. The most recent close on file for QNRX is $7.26, dated September 4, 2026. That is −$0.61 (−7.75%) against the previous close. The latest close sits 123.38% above that 52-week low.

Financial Health

The most recent full year on file, fiscal 2025, shows revenue of $0.00. The same year closed with a net loss of $15.80M. The reported profit margin is 0%. Earnings per share on a trailing basis come to −5.67.

Across the 4 fiscal years on file, revenue moves from $0.00 in 2022 to $0.00 in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published.

Over the trailing twelve months the price has returned −4.79%. Measured over 10 years, that is −66.94% a year compounded. The reported beta is 1.73. Annualized volatility over the trailing 10 years is 172.1%.

Growth & Income

No dividend is on file for QNRX.

2026 is still running; the price is −49.69% year to date. Across the complete calendar years on file, 2017 returned +126.54% and 2022 returned −93.76%. Of the 9 complete calendar years on file, 1 finished higher.

Peer Comparison

Quoin Pharmaceuticals, Ltd. (QNRX) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company	Ticker	Market Cap	P/E Ratio
Quoin Pharmaceuticals, Ltd.	QNRX	$14.58M	—
Vertex Pharmaceuticals Incorporated	VRTX	$138.42B	32.5
Regeneron Pharmaceuticals, Inc.	REGN	$85.22B	20.5
argenx SE	ARGX	$64.25B	40.1

The Biotechnology industry average P/E ratio is 12.6x. Quoin Pharmaceuticals, Ltd. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

ARGX

argenx SE

$64.25B

MRNA

Moderna, Inc.

$58.11B

RVMD

Revolution Medicines, Inc.

$45.01B

ONC

BeOne Medicines AG

$40.53B

View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

JNJ

Johnson & Johnson

$663.28B

ABBV

AbbVie Inc.

$453.19B

MRK

Merck & Co., Inc.

$370.89B

UNH

UnitedHealth Group Incorporated

$356.47B

View all Healthcare stocks →

About Quoin Pharmaceuticals, Ltd.

Quoin Pharmaceuticals, Ltd., a late-stage specialty pharmaceutical company, focuses on the development and commercialization of therapeutic products for rare and orphan diseases in the United States. The company's lead product is QRX003, a topical lotion, which is in phase 2 to treat netherton syndrome (NS); phase 1 in to treat peeling skin syndrome; and in pre-clinical stage to treat SAM syndrome and ichthyosis. It also develops QRX008 for the treatment of scleroderma, which is in pre-clinical stage; and QRX009, to treat microcystic lymphatic malformations, venous malformations, angiofibroma, and other diseases. It has a research agreement with Queensland University of Technology. Quoin Pharmaceuticals, Ltd. was founded in 2018 and is based in Ashburn, Virginia. Quoin Pharmaceuticals, Ltd. is a subsidiary of Skinvisible, Inc.

Visit website →

Quoin Pharmaceuticals, Ltd. (QNRX) Stock Analysis